The clozapine metabolite N-desmethylclozapine displays variable activity in diverse functional assays at human dopamine D 2 and serotonin 5-HT 1A receptors

European Journal of Pharmacology

Volumn 669, Issue 1-3, 2011, Pages 51-58

  Heusler, Peter ^a   Bruins Slot, Liesbeth ^a   Tourette, Amélie ^a   Tardif, Stéphanie ^a   Cussac, Didier ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antipsychotics; Clozapine; Dopamine D 2 receptor; N desmethylclozapine; Serotonin 5 HT 1A receptor

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; BUSPIRONE; CALCIUM ION; CARIPRAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NORCLOZAPINE; PINDOLOL; PRECLAMOL; QUINPIROLE; SEROTONIN 1A RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; XENOPUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALCIUM; CELLS, CULTURED; CHO CELLS; CLOZAPINE; CRICETINAE; CRICETULUS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OOCYTES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; XENOPUS LAEVIS;

EID: 80053314970     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.07.031     Document Type: Article

References (50)

1. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J. Psychopharmacol. 15 2001 37 46 (Pubitemid 32242102)
2. + channels Proc. Natl. Acad. Sci. U. S. A. 100 2003 6239 6244 (Pubitemid 36576960)
3. D. Bishara, and D. Taylor Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability Drugs 68 2008 2269 2292
4. 2S receptors coupled to extracellular signal-regulated kinase Eur. J. Pharmacol. 534 2006 63 70 (Pubitemid 43384184)
5. + channel currents J. Biol. Chem. 276 2001 47512 47517
6. 3 partial agonist J. Pharmacol. Exp. Ther. 315 2005 1278 1287 (Pubitemid 41635416)
7. R.R. Conley, and D.L. Kelly Management of treatment resistance in schizophrenia Biol. Psychiatry 50 2001 898 911 (Pubitemid 34020701)
8. L. Couchman, P.E. Morgan, E.P. Spencer, and R.J. Flanagan Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007 Ther. Drug Monit. 32 2010 438 447
9. 1A receptors Psychopharmacology (Berl) 162 2002 168 177 (Pubitemid 34743956)
10. 1A receptor properties compared with conventional and atypical antipsychotics Soc. Neurosci. Abstr. 2008, poster presentation 155.9 2008
11. 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology J. Pharmacol. Exp. Ther. 331 2009 222 233
12. A. Farah Atypicality of atypical antipsychotics Prim. Care Companion. J. Clin. Psychiatry 7 2005 268 274 (Pubitemid 44371604)
13. D.M. Gardner, R.J. Baldessarini, and P. Waraich Modern antipsychotic drugs: a critical overview CMAJ 172 2005 1703 1711 (Pubitemid 40896865)
14. P.M. Haddad, and S.G. Sharma Adverse effects of atypical antipsychotics: differential risk and clinical implications CNS. Drugs 21 2007 911 936 (Pubitemid 47557106)
15. 35S]GTPγS binding assay: approaches and applications in pharmacology Life Sci. 74 2003 489 508 (Pubitemid 37377904)
16. 2 receptor partial agonist Eur. J. Pharmacol. 552 2006 36 45 (Pubitemid 44648072)
17. 1A receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling Neuropharmacology 49 2005 963 976 (Pubitemid 41503296)
18. 2L receptors coupled to GIRK potassium channels Neuropharmacology 52 2007 1106 1113
19. 4.4 receptors: differential pathway-dependent potencies of receptor agonists Naunyn Schmiedebergs Arch. Pharmacol. 379 2009 87 99
20. q-coupled m1 muscarinic acetylcholine receptor J. Biol. Chem. 276 2001 5505 5510
21. C.A. Jones, and A.C. McCreary Serotonergic approaches in the development of novel antipsychotics Neuropharmacology 55 2008 1056 1065
22. R. Joober, and P. Boksa Clozapine: a distinct, poorly understood and under-used molecule J. Psychiatry Neurosci. 35 2010 147 149
23. 2 receptor signaling Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 348 356 (Pubitemid 46209412)
24. 2 receptors Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1081 1090 (Pubitemid 37464954)
25. D.H. Kim, M.J. Maneen, and S.M. Stahl Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia Neurotherapeutics 6 2009 78 85
26. A. Kovoor, D.J. Henry, and C. Chavkin Agonist-induced desensitization of the μ opioid receptor-coupled potassium channel (GIRK1) J. Biol. Chem. 270 1995 589 595
27. 1C receptor antagonists Eur. J. Pharmacol. 245 1993 179 182 (Pubitemid 23115053)
28. J. Lameh, E.S. Burstein, E. Taylor, D.M. Weiner, K.E. Vanover, and D.W. Bonhaus Pharmacology of N-desmethylclozapine Pharmacol. Ther. 115 2007 223 231 (Pubitemid 47042913)
29. R.B. Mailman, and V. Murthy Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr. Pharm. Des. 16 2010 488 501
30. i/o pathways Neuropharmacology 39 2000 2360 2373 (Pubitemid 30642779)
31. 1A receptors improve cognition in schizophrenia? Behav. Brain Res. 195 2008 98 102
32. M.C. Mendoza, and J.P. Lindenmayer N-desmethylclozapine: is there evidence for its antipsychotic potential? Clin. Neuropharmacol. 32 2009 154 157
33. 1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis J. Pharmacol. Exp. Ther. 311 2004 190 203 (Pubitemid 39287799)
34. S. Natesan, G.E. Reckless, K.B. Barlow, J.N. Nobrega, and S. Kapur Evaluation of N-desmethylclozapine as a potential antipsychotic-preclinical studies Neuropsychopharmacology 32 2007 1540 1549 (Pubitemid 46920156)
35. 1A receptors Neuropharmacology 35 1996 119 121
36. + channel modulation in transfected cells Int. J. Neuropsychopharmacol. 11 2008 293 307 (Pubitemid 351482503)
37. 3 receptors: potential role of heterodimer formation J. Neurochem. 102 2007 1410 1424 (Pubitemid 47174247)
38. 1A receptor agonists in recombinant cell lines. Modulation of apparent efficacy by G-protein activation state Naunyn Schmiedebergs Arch. Pharmacol. 356 1997 551 561 (Pubitemid 27478957)
39. 2short receptor: dopamine-bound versus antagonist-bound receptor states J. Pharmacol. Exp. Ther. 297 2001 133 140 (Pubitemid 32242572)
40. M. Pirmohamed, D. Williams, S. Madden, E. Templeton, and B.K. Park Metabolism and bioactivation of clozapine by human liver in vitro J. Pharmacol. Exp. Ther. 272 1995 984 990
41. B.L. Roth, D.J. Sheffler, and W.K. Kroeze Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discov. 3 2004 353 359 (Pubitemid 38499762)
42. 4 receptor pharmacology using GIRK channel coupling in Xenopus oocytes Eur. J. Pharmacol. 591 2008 52 58
43. 2 atypical antipsychotics Am. J. Psychiatry 162 2005 1984 1985 (Pubitemid 41428639)
44. + channel, GIRK, in Xenopus oocytes J. Gen. Physiol. 109 1997 477 490 (Pubitemid 27164465)
45. 2A receptor inverse agonist J. Pharmacol. Exp. Ther. 332 2010 622 631
46. P.G. Strange Antipsychotic drug action: antagonism, inverse agonism or partial agonism Trends Pharmacol. Sci. 29 2008 314 321
47. 2S receptors render it a unique antipsychotic Eur. J. Pharmacol. 515 2005 10 19 (Pubitemid 40779262)
48. + channel (GIRK) in Xenopus oocytes Pflugers Arch. 436 1998 56 68 (Pubitemid 28206316)
49. D.M. Weiner, H.Y. Meltzer, I. Veinbergs, E.M. Donohue, T.A. Spalding, T.T. Smith, N. Mohell, S.C. Harvey, J. Lameh, N. Nash, K.E. Vanover, R. Olsson, K. Jayathilake, M. Lee, A.I. Levey, U. Hacksell, E.S. Burstein, R.E. Davis, and M.R. Brann The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine Psychopharmacology (Berl) 177 2004 207 216 (Pubitemid 40109932)
50. i-coupled muscarinic m2 receptors in Xenopus oocytes: the role of receptor precoupling in RGS modulation J. Physiol. 545 2002 355 373 (Pubitemid 36004372)